SNV4818 in Participants With Advanced Solid Tumors

Inclusion Criteria: * Advanced or metastatic solid tumor with an activating PIK3CA mutation. * Refractory to or intolerant of available therapies * Disease measurable by RECIST 1.1 criteria, or disease evaluable by clinically relevant tumor biomarkers in blood. * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 Exclusion Criteria: * Diagnosis of a primary CNS malignancy * Active brain metastases or carcinomatous meningitisBrain metastases * Type 1 diabetes mellitus or uncontrolled type 2 diabetes mellitusDiabetes * Inadequate organ function * Clinically significant ECG abnormalities, including QTcF ≥ 470 msCardiac